Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Celine Pitou"'
Autor:
Matthew P. Goetz, Edward M. Chan, Daphne L. Farrington, Lynette B. Mulle, Celine Pitou, Palaniappan Kulanthaivel, Peipei Shi, Robert Bell, Louis F. Stancato, Xuekui Zhang, Sameera R. Wijayawardana, Claudia S. Kelly, Rebecca R. Arcos, Drew W. Rasco, Julian R. Molina, Muralidhar Beeram, Janet L. Lensing, Kyriakos P. Papadopoulos, Charles Erlichman, Anthony W. Tolcher, Paul Haluska, Amita Patnaik
Table S1:Summary of baseline pathological diagnosis; Table S2:Noncompartmental Pharmacokinetic Summary Following Oral Administration of ralimetinib on Day 1 and on Day 14 (Cycle 1) - Capsule Formulation; Table S3: Noncompartmental Pharmacokinetic Sum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2281bd2046434dc36c6b4e4cf95b4ec3
https://doi.org/10.1158/1078-0432.22457877
https://doi.org/10.1158/1078-0432.22457877
Autor:
Matthew P. Goetz, Edward M. Chan, Daphne L. Farrington, Lynette B. Mulle, Celine Pitou, Palaniappan Kulanthaivel, Peipei Shi, Robert Bell, Louis F. Stancato, Xuekui Zhang, Sameera R. Wijayawardana, Claudia S. Kelly, Rebecca R. Arcos, Drew W. Rasco, Julian R. Molina, Muralidhar Beeram, Janet L. Lensing, Kyriakos P. Papadopoulos, Charles Erlichman, Anthony W. Tolcher, Paul Haluska, Amita Patnaik
Trial Profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c4fdfd5005a4d1bdbf0015d98faa0d
https://doi.org/10.1158/1078-0432.22457880.v1
https://doi.org/10.1158/1078-0432.22457880.v1
Autor:
Matthew P. Goetz, Edward M. Chan, Daphne L. Farrington, Lynette B. Mulle, Celine Pitou, Palaniappan Kulanthaivel, Peipei Shi, Robert Bell, Louis F. Stancato, Xuekui Zhang, Sameera R. Wijayawardana, Claudia S. Kelly, Rebecca R. Arcos, Drew W. Rasco, Julian R. Molina, Muralidhar Beeram, Janet L. Lensing, Kyriakos P. Papadopoulos, Charles Erlichman, Anthony W. Tolcher, Paul Haluska, Amita Patnaik
Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1477de6dd7ffed937a7c180d098962
https://doi.org/10.1158/1078-0432.c.6523734
https://doi.org/10.1158/1078-0432.c.6523734
Autor:
Andrea Wang-Gillam, Anis A. Khan, Dan Wang, Mythili Koneru, Mark H. O'Hara, Celine Pitou, Wei Zhang, Burkhard Vangerow, Anna M. Szpurka, Hedy L. Kindler, Sheng-Bin Peng, Wells A. Messersmith
Publikováno v:
Journal of Pancreatic Cancer
Purpose: This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tolerability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients with advanced refractory solid tumors.
Autor:
Amy S. Paller, Kimberley Jackson, Marieke M B Seyger, Claudia Rodriguez Capriles, Perla Lansang, Kim A. Papp, Nieves Velez de Mendizabal, Laiyi Chua, Celine Pitou
Publikováno v:
British Journal of Clinical Pharmacology, 88, 1074-1086
British Journal of Clinical Pharmacology, 88, 3, pp. 1074-1086
British Journal of Clinical Pharmacology, 88, 3, pp. 1074-1086
Contains fulltext : 248294.pdf (Publisher’s version ) (Open Access) AIMS: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A used in the treatment of adult and paediatric patients with moderate-to-severe psor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e731f2bb601ccea9fce16a6c24a136e
http://hdl.handle.net/2066/248294
http://hdl.handle.net/2066/248294
Autor:
Sanjay Chabra, B. J. Gill, Gaia Gallo, Danting Zhu, Celine Pitou, Christopher D. Payne, Ana Accioly, Luis Puig
Publikováno v:
ADVANCES IN THERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Introduction Subcutaneous (SC) injection is a common route of drug administration; however, injection site pain (ISP) might create a negative patient experience. We evaluated ISP, bioequivalence, and overall safety of the citrate-free (CF) formulatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7330e2716abf3817463efd15fe21496
https://ddd.uab.cat/record/277645
https://ddd.uab.cat/record/277645
Autor:
Xuejing Wang, Katherine M Bell-McGuinn, Jimmy Hwang, Johanna C. Bendell, Hans Christian Reinhardt, Daphne L. Farrington, Celine Pitou, Helge Bischoff, Robert M. Campbell, Thomas Zander, Scott M. Hynes, Philip W. Iversen, Michael Thomas
Publikováno v:
Investigational New Drugs. 38:1145-1155
Purpose The primary objective was to determine the recommended Phase 2 dose (RP2D) of checkpoint kinase 1 inhibitor, prexasertib, in combination with the p38 mitogen-activated protein kinase inhibitor, ralimetinib, which may be safely administered to
Autor:
Alan L. Ho, Johanna C. Bendell, Daniel D. Von Hoff, Ragini R. Kudchadkar, Valerie Andre, Ramon V. Tiu, Les H. Brail, Jeffrey R. Infante, Trevor Tucker, Celine Pitou, Michael R. Migden
Publikováno v:
Clinical Cancer Research. 24:2082-2091
Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe administration to patients with locally advanced/metastatic cancer. Experimental Design: This was a phase I, multicenter, o
Autor:
Celine Pitou, Victor Mangas-Sanjuan, Johan Wallin, Zinnia P. Parra-Guillen, Maria Garcia-Cremades, Gary Mo, Iñaki F. Trocóniz, Philip W. Iversen
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 366:96-104
Xenograft mice are largely used to evaluate the efficacy of oncological drugs during preclinical phases of drug discovery and development. Mathematical models provide a useful tool to quantitatively characterize tumor growth dynamics and also optimiz
Publikováno v:
European Journal of Pharmaceutical Sciences. 115:296-303
The aim of this evaluation was to characterize the impact of the tumour size (TS) effects driven by the anticancer drug gemcitabine on overall survival (OS) in patients with advanced pancreatic cancer by building and validating a predictive semi-mech